Blood first line ready screening trial ( B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic

Overview

cited authors

Mok, T. S. K.; Gadgeel, S.; Kim, E. S.; Velcheti, V.; Hu, S.; Riehl, T.; Schleifman, E.; Paul, S. M.; Mocci, S.; Shames, D. S.; Phan, S.; Yun, C.; Mathisen, M.; Kowanetz, M.; Sweere, U.; Socinski, M. A.

authors

Socinski, Mark A., MD

Publication Date

September 1, 2017

webpage

Web of Science

published in

ANNALS OF ONCOLOGY Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.